Total Payments
$344,532
2024 Payments
$116,491
Companies
39
Transactions
790
Medicare Patients
7,366
Medicare Billing
$2.5M
Payment Breakdown by Category
Other$247,264 (71.8%)
Travel$68,968 (20.0%)
Food & Beverage$15,010 (4.4%)
Consulting$10,920 (3.2%)
Research$2,085 (0.6%)
Education$284.74 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $182,133 | 116 | 52.9% |
| Travel and Lodging | $68,968 | 136 | 20.0% |
| Honoraria | $65,131 | 33 | 18.9% |
| Food and Beverage | $15,010 | 496 | 4.4% |
| Consulting Fee | $10,920 | 3 | 3.2% |
| Unspecified | $2,085 | 1 | 0.6% |
| Education | $284.74 | 5 | 0.1% |
Payments by Type
General
$342,447
789 transactions
Research
$2,085
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $75,213 | 143 | $0 (2024) |
| Amgen Inc. | $71,144 | 109 | $0 (2024) |
| CALLIDITAS THERAPEUTICS US INC. | $67,822 | 57 | $0 (2024) |
| Relypsa, Inc. | $27,095 | 97 | $0 (2020) |
| Lilly USA, LLC | $23,810 | 25 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $21,617 | 43 | $0 (2024) |
| Keryx Biopharmaceuticals, Inc. | $17,460 | 28 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13,621 | 41 | $0 (2024) |
| Vifor Pharma, Inc. | $11,206 | 32 | $0 (2023) |
| AKEBIA THERAPEUTICS INC | $8,764 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $116,491 | 205 | CALLIDITAS THERAPEUTICS US INC. ($43,128) |
| 2023 | $81,372 | 150 | Amgen Inc. ($43,455) |
| 2022 | $12,665 | 79 | Fresenius USA Marketing, Inc. ($6,022) |
| 2021 | $28,055 | 80 | AstraZeneca Pharmaceuticals LP ($16,888) |
| 2020 | $34,155 | 57 | AstraZeneca Pharmaceuticals LP ($27,493) |
| 2019 | $34,822 | 105 | AstraZeneca Pharmaceuticals LP ($25,550) |
| 2018 | $30,581 | 80 | Relypsa, Inc. ($18,414) |
| 2017 | $6,392 | 34 | Keryx Biopharmaceuticals, Inc. ($6,045) |
All Payment Transactions
790 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Consulting Fee | Cash or cash equivalent | $5,720.00 | General |
| Category: Nephrology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $23.88 | General |
| 12/18/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: NEPHROLOGY | ||||||
| 12/10/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $850.00 | General |
| Category: Nephrology | ||||||
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $69.99 | General |
| Category: Nephrology | ||||||
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $54.98 | General |
| Category: Nephrology | ||||||
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: Nephrology | ||||||
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: Nephrology | ||||||
| 12/06/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Travel and Lodging | In-kind items and services | $520.96 | General |
| Category: Nephrology | ||||||
| 12/06/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Travel and Lodging | In-kind items and services | $292.67 | General |
| Category: Nephrology | ||||||
| 12/06/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $119.51 | General |
| Category: Nephrology | ||||||
| 12/04/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.51 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $16.00 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $15.96 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | In-kind items and services | $542.55 | General |
| Category: Inflammation | ||||||
| 11/15/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | In-kind items and services | $249.96 | General |
| Category: Inflammation | ||||||
| 11/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $7.11 | General |
| Category: DIABETES | ||||||
| 11/08/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | In-kind items and services | $672.27 | General |
| Category: Inflammation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $2,085 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,650 | 4,664 | $1.5M | $487,642 |
| 2022 | 15 | 1,768 | 5,111 | $1.5M | $599,839 |
| 2021 | 13 | 1,841 | 5,559 | $1.7M | $690,422 |
| 2020 | 14 | 2,107 | 6,225 | $1.9M | $696,224 |
Total Patients
7,366
Total Services
21,559
Medicare Billing
$2.5M
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 105 | 592 | $410,644 | $150,212 | 36.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 384 | 1,780 | $282,140 | $106,480 | 37.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 320 | 407 | $142,520 | $51,932 | 36.4% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 91 | 225 | $131,604 | $46,626 | 35.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 346 | 771 | $194,137 | $45,329 | 23.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 107 | 441 | $63,482 | $23,488 | 37.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Facility | 2023 | 19 | 80 | $189,520 | $20,191 | 10.7% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 22 | 90 | $51,696 | $18,316 | 35.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 75 | 75 | $25,156 | $8,066 | 32.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 57 | $13,610 | $5,194 | 38.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 37 | $9,718 | $3,582 | 36.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 48 | $17,280 | $3,281 | 19.0% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 19 | 20 | $7,960 | $2,562 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 27 | $4,729 | $1,508 | 31.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $3,148 | $874.86 | 27.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 144 | 899 | $546,557 | $245,990 | 45.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 436 | 1,993 | $279,020 | $108,818 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 302 | 575 | $123,625 | $51,230 | 41.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 288 | 346 | $138,300 | $50,858 | 36.8% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 26 | 143 | $67,210 | $31,717 | 47.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 150 | 571 | $81,653 | $31,429 | 38.5% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 75 | 128 | $60,416 | $29,113 | 48.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Facility | 2022 | 18 | 57 | $128,581 | $15,688 | 12.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 70 | 70 | $22,750 | $7,997 | 35.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 61 | 72 | $19,440 | $7,321 | 37.7% |
About Dr. Anand Reddy, MD
Dr. Anand Reddy, MD is a Nephrology healthcare provider based in Odessa, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1780892760.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anand Reddy, MD has received a total of $344,532 in payments from pharmaceutical and medical device companies, with $116,491 received in 2024. These payments were reported across 790 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($182,133).
As a Medicare-enrolled provider, Reddy has provided services to 7,366 Medicare beneficiaries, totaling 21,559 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Odessa, TX
- Active Since 05/21/2007
- Last Updated 12/08/2022
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780892760
Products in Payments
- LOKELMA (Drug) $72,580
- TARPEYO (Drug) $67,822
- TAVNEOS (Drug) $67,307
- Veltassa (Drug) $38,295
- JARDIANCE (Drug) $37,374
- Velphoro (Drug) $21,325
- Auryxia (Drug) $17,487
- Vafseo (Drug) $6,835
- Tavneos (Drug) $3,757
- FARXIGA (Drug) $2,616
- AURYXIA (Drug) $1,902
- RAYALDEE (Drug) $974.73
- Nephrocheck (Device) $292.19
- SAMSCA (Drug) $287.01
- JYNARQUE (Drug) $252.13
- BENLYSTA (Biological) $238.06
- Rayaldee (Drug) $221.96
- LUPKYNIS (Drug) $210.20
- Kerendia (Drug) $181.42
- XPHOZAH 30 MG (Drug) $144.33
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Odessa
Dr. Asif Ansari, Md, MD
Nephrology — Payments: $5,230
Nephrology $5,230
Mamoun Bashir, Md, MD
Nephrology — Payments: $978.06
Nephrology $978.06
Dr. Henry Ntende, Md, MD
Nephrology — Payments: $568.29
Nephrology $568.29
Dr. Ronald Gibbons, M.d., Mba, M.D., MBA
Nephrology — Payments: $382.02
Nephrology $382.02